Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators ... is based on research showing the medicine, called inavolisib, could offer a ...

Roche's Itovebi was the first PI3K inhibitor to get approved ... has an FDA green light as part of a combination regimen for patients with advanced HR-positive, HER2-negative breast cancer with ...

Basel, 29 May 2024 - Roche (SIX ... or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. The Priority Review is based on the ...

A second Phase III INAVO122 study (NCT05894239) is evaluating Itovebi in combination with Roche’s other FDA-approved breast cancer therapy Phesgo (pertuzumab, trastuzumab, and rHuPH20 ...

How Does Orserdu Work in Breast ... Your cancer has grown while or after you took at least one other cancer hormonal medicine. Your doctor will test your cancer for gene changes and review your ...